

Press Release

October 31, 2025

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Announces Variances Between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2025, and Revisions to Its Financial Forecasts for the Year Ending March 31, 2026

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Toru Kimura; Securities Code: 4506, Prime Market of TSE) announced today that variance occurred between its financial forecasts for the half-year ended September 30, 2025, which were announced on July 31, 2025, and the financial results for the period announced today.

The Company also announced that it has revised its financial forecasts for the fiscal year ending March 31, 2026, which were announced on May 13, 2025, in light of recent performance trends.

1. Variances Between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2025 (April 1, 2025 to September 30, 2025)

(Millions of yen)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
Previous Forecasts (A)	207,000	70,000	69,000	56,000	¥140.96
Revised Forecasts (B)	227,122	96,084	96,157	98,860	¥248.84
Variance in amount (B—A)	20,122	26,084	27,157	42,860	—
Variance in percent (%)	9.7	37.3	39.4	76.5	—
[Reference] Same period a year ago (Half-year ended September 30, 2024)	180,749	(38)	(8,179)	(32,229)	¥(81.12)

2. Revisions to Its Financial Forecasts for the Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(Millions of yen)

	Revenue	Core operating profit	Operating profit	Net profit attributable to owners of the parent	Basic earnings per share
Previous Forecasts (A)	355,000	56,000	54,000	40,000	¥100.68
Revised Forecasts (B)	429,000	97,000	98,000	92,000	¥231.57
Variance in amount (B—A)	74,000	41,000	44,000	52,000	—
Variance in percent (%)	20.8	73.2	81.5	130.0	—
[Reference] Previous year (Year ended March 31, 2025)	398,832	43,153	28,804	23,634	¥59.49

Note: Core operating profit is calculated by deducting from operating profit any gains and losses resulting from nonrecurring factors, including changes in fair value of contingent consideration, impairment losses, and business structure improvement expenses.

3. Reasons for the variances and the revisions

(1) The half-year ended September 30, 2025

Revenue exceeded the previously announced forecast primarily due to strong sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) in the North America segment. On the other hand, selling, general and administrative expenses and R&D expenses were lower than expected, resulting in some expenses likely being recorded in the second half of the fiscal year.

Consequently, for the six-month period ended September 30, 2025, revenue increased by 20.1 billion JPY to 227.1 billion JPY, core operating profit increased by 26.1 billion JPY to 96.1 billion JPY, and operating profit increased by 27.2 billion JPY to 96.2 billion JPY from the previous forecasts.

Net profit attributable to owners of the parent increased by 42.9 billion JPY from the previous forecast to 98.9 billion JPY, due to increased operating profit, improved financial income/costs resulting from the weaker-than-expected Japanese yen, and the recording of a gain on the reversal of deferred tax liabilities.

(2) The fiscal year ending March 31, 2026

Revenue has been revised upward by 74.0 billion JPY from the previous forecast to 429.0 billion JPY, reflecting the expectation of continued strong sales in North America.

Core operating profit has been revised upward by 41.0 billion JPY from the previous forecast to 97.0 billion JPY, as the gains from the divestiture of the Asian business are expected to exceed initial forecast, while gross profit is expected to increase due to revenue growth.

Operating profit has been revised upward by 44.0 billion JPY to 98.0 billion JPY from the previous forecast due to increased core operating profit, and net profit attributable to owners of the parent has been revised upward by 52.0 billion JPY to 92.0 billion JPY, taking into account a decrease in tax expenses and other costs in the first half of the fiscal year.

The full-year foreign exchange assumption (average exchange rate for the period) remains unchanged from the previous forecast at 145.0 JPY against 1 USD.

Disclaimer Regarding Forward-looking Statements

The statements made in this press release contain forward-looking statements based on management's assumptions and beliefs in light of information available as of the day of this release, which involve both known and unknown risks and uncertainties. Actual results of those matters covered in the forward-looking statements including financial forecast may differ materially from those contained in this release, due to a number of factors.

Contact:

Corporate Communications
Sumitomo Pharma Co., Ltd.
E-mail: prir@sumitomo-pharma.co.jp.